About Us

GliaMed is a development-stage biopharmaceutical company dedicated to the discovery and development of small molecule drugs which enhance the human body’s innate ability to regenerate. Founded in 2001, the company is focused on the development of compounds termed Regenerative Immunophilin Ligands or RILs. In preclinical models, treatment with RILs has been shown to induce the localized expression of transcription factors characteristic of pluripotent stem cells at the site of acute disease or trauma. The company has shown that these cells can then be reprogrammed by local signals to become neurons, cardiac myocytes, chondrocytes, blood vessels or other cell types, as appropriate, which then contribute to fully differentiated tissues such as skin.